{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:55:48Z","timestamp":1783540548285,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.virusres.2023.199039","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T02:20:39Z","timestamp":1672798839000},"page":"199039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Lessons from resistance analysis in clinical trials of IV zanamivir"],"prefix":"10.1016","volume":"325","author":[{"given":"Phillip J","family":"Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalini","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F","family":"Peppercorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.virusres.2023.199039_bib0001","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3851\/IMP3344","article-title":"Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient","volume":"24","author":"Abed","year":"2019","journal-title":"Antivir. Ther."},{"issue":"12","key":"10.1016\/j.virusres.2023.199039_bib0002","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/135965350701200S04.1","article-title":"Influenza virus susceptibility and resistance to oseltamivir","author":"Aoki","year":"2007","journal-title":"Antivir. Ther."},{"issue":"5","key":"10.1016\/j.virusres.2023.199039_bib0004","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2727","article-title":"Intravenous Zanamivir in Hospitalized Patients With Influenza","volume":"140","author":"Bradley","year":"2017","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.virusres.2023.199039_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119115","article-title":"Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.virusres.2023.199039_bib0006","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1128\/AAC.03667-14","article-title":"Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient","volume":"58","author":"Eshaghi","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virusres.2023.199039_bib0007","unstructured":"Food and Drug Administration. 2006. Guidance for Industry Antiviral Product Development \u2014 Conducting and Submitting Virology Studies to the Agency. https:\/\/www.fda.gov\/media\/71223\/download."},{"key":"10.1016\/j.virusres.2023.199039_bib0008","doi-asserted-by":"crossref","unstructured":"Govorkova, E.A. Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses. Influenza Other Respir. Viruses. 2013 Jan;7 Suppl 1(Suppl 1):50\u20137. doi: 10.1111\/irv.12044. PMID: 23279897; PMCID: PMC4942988.","DOI":"10.1111\/irv.12044"},{"issue":"1","key":"10.1016\/j.virusres.2023.199039_bib0009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3851\/IMP2811","article-title":"Primarily oseltamivir-resistant influenza A (H1N1pdm09) virus evolving into a multidrug-resistant virus carrying H275Y and I223R neuraminidase substitutions","volume":"20","author":"Grund","year":"2015","journal-title":"Antivir. Ther. (Lond.)"},{"key":"10.1016\/j.virusres.2023.199039_bib0010","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1086\/314440","article-title":"Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus","volume":"178","author":"Gubareva","year":"1998","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.virusres.2023.199039_bib0011","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3851\/IMP1678","article-title":"Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro","volume":"15","author":"Gubareva","year":"2010","journal-title":"Antivir. Ther. (Lond.)"},{"issue":"13","key":"10.1016\/j.virusres.2023.199039_bib0012","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jama.297.13.1435","article-title":"Emergence of Influenza B viruses with reduced sensitivity to neuraminidase inhibitors","volume":"297","author":"Hatakeyama","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.virusres.2023.199039_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.antiviral.2006.10.004","article-title":"Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes","volume":"73","author":"Hurt","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virusres.2023.199039_bib0015","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/500465","article-title":"Recovery of drug-resistant influenza virus from immunocompromised patients: a case series","volume":"193","author":"Ison","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.virusres.2023.199039_bib0016","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/135965350801300602","article-title":"Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies","volume":"13","author":"Lackenby","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virusres.2023.199039_bib0017","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.clinthera.2007.08.023","article-title":"Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling high-risk adult and adolescent subjects: a 28-day, randomized, double -blind, placebo-controlled, multi-center trial","volume":"29","author":"Laforce","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.virusres.2023.199039_bib0019","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/600383","article-title":"Viral loads and duration of viral shedding in adult patients hospitalized with influenza","volume":"200","author":"Lee","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.virusres.2023.199039_bib0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/QCO.0000000000000498","article-title":"Neuraminidase inhibitor resistance in influenza: a clinical perspective","volume":"31","author":"Lee","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.virusres.2023.199039_bib0021","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/infdis\/jiv288","article-title":"E119D neuraminidase mutation conferring pan-resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient","volume":"212","author":"L'Huillier","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2023.199039_bib0022","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.3390\/v7092850","article-title":"Clinical implications of antiviral resistance in influenza","volume":"7","author":"Li","year":"2015","journal-title":"Viruses"},{"issue":"45","key":"10.1016\/j.virusres.2023.199039_bib0023","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.45.30060","article-title":"Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring","volume":"20","author":"Little","year":"2015","journal-title":"Euro Surveill."},{"issue":"1 October","key":"10.1016\/j.virusres.2023.199039_bib0024","first-page":"71","article-title":"Favipiravir and Zanamivir cleared infection with influenza B in a severely immunocompromised child","author":"Lumby","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.virusres.2023.199039_bib0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/infdis\/jit467","article-title":"Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study","volume":"15","author":"Marty","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.virusres.2023.199039_bib0026","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2213-2600(16)30435-0","article-title":"Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial","volume":"5","author":"Marty","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.virusres.2023.199039_bib0028","first-page":"25","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2012","journal-title":"Influenza Other Respir. Viruses"},{"issue":"7","key":"10.1016\/j.virusres.2023.199039_bib0029","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1128\/AAC.01339-05","article-title":"Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use","volume":"50","author":"Monto","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.virusres.2023.199039_bib0030","doi-asserted-by":"crossref","first-page":"21846","DOI":"10.7448\/IAS.20.1.21846","article-title":"Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014","volume":"20","author":"Moscona","year":"2017","journal-title":"J. Int. AIDS Soc."},{"issue":"5","key":"10.1016\/j.virusres.2023.199039_bib0031","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/AAC.01773-10","article-title":"Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus","volume":"55","author":"Naughtin","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virusres.2023.199039_bib0032","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1086\/656439","article-title":"Recovery of a multi-drug resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y\/I223R mutation from a child after prolonged treatment with oseltamivir","volume":"51","author":"Nguyen","year":"2010","journal-title":"Clin. Inf. Dis."},{"issue":"1 Pt B","key":"10.1016\/j.virusres.2023.199039_bib0033","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3851\/IMP2067","article-title":"Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods","volume":"17","author":"Nguyen","year":"2012","journal-title":"Antivir. Ther."},{"issue":"5","key":"10.1016\/j.virusres.2023.199039_bib0034","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/irv.12113","article-title":"Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season","volume":"7","author":"Okomo-Adhiambo","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.virusres.2023.199039_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.10.009","article-title":"Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency","volume":"160","author":"Pichon","year":"2018","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/j.virusres.2023.199039_bib0036","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1128\/JCM.01641-14","article-title":"Exploring the potential of next-generation sequencing in detection of respiratory viruses","volume":"52","author":"Prachayangprecha","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.virusres.2023.199039_bib0037","author":"Rousset","year":"2010"},{"issue":"9","key":"10.1016\/j.virusres.2023.199039_bib0038","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.00555-08","article-title":"Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008","volume":"52","author":"Sheu","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virusres.2023.199039_bib0039","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/infdis\/jiv245","article-title":"Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir","volume":"212","author":"Tamura","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.virusres.2023.199039_bib0040","doi-asserted-by":"crossref","first-page":"30445","DOI":"10.2807\/1560-7917.ES.2017.22.3.30445","article-title":"Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014","volume":"22","author":"Trebbien","year":"2017","journal-title":"Euro Surveill."},{"key":"10.1016\/j.virusres.2023.199039_bib0041","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3851\/IMP1635","article-title":"Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus","volume":"15","author":"Valinotto","year":"2010","journal-title":"Antiviral Ther."},{"issue":"14","key":"10.1016\/j.virusres.2023.199039_bib0042","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMc1003749","article-title":"Emergence of a multi-drug resistant pandemic influenza A (H1N1) virus","volume":"363","author":"van der Vries","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.virusres.2023.199039_bib0043","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.tibtech.2019.09.009","article-title":"Next-Generation sequencing: an eye opener for the surveillance of antiviral resistance","volume":"38","author":"Van Poelvoorde","year":"2020","journal-title":"Trends Biotechnol."},{"issue":"3","key":"10.1016\/j.virusres.2023.199039_bib0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/irv.12947","article-title":"Zanamivir aqueous solution in severe influenza: a global Compassionate Use Program, 2009-2019","volume":"16","author":"Wang-Jairaj","year":"2022","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.virusres.2023.199039_bib0047","unstructured":"World Health Organisation, 2012. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly. Epidemiol. Rec.;87:369\u201374."},{"key":"10.1016\/j.virusres.2023.199039_bib0048","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.antiviral.2016.08.023","article-title":"Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects","author":"Yates","year":"2016","journal-title":"Antiviral Res."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170223000011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170223000011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:19:10Z","timestamp":1759155550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170223000011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":42,"alternative-id":["S0168170223000011"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2023.199039","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons from resistance analysis in clinical trials of IV zanamivir","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2023.199039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199039"}}